9.1: Bioavailability: Overview

作者：

简介：

Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in lower bioavailability due to factors such as absorption barriers and metabolic processes.

When a drug is administered orally, it must traverse the gastrointestinal tract, where it undergoes absorption and metabolic processes. The bioavailability of oral drugs depends on several factors, including:

Enzyme Activity in the Gut Wall and Liver: The drug may be metabolized by enzymes in the intestinal wall or liver before reaching systemic circulation, a process termed first-pass metabolism. Drugs such as lidocaine and propranolol are significantly metabolized during this phase, rendering oral administration ineffective.
Gastric pH: The acidic or basic nature of the stomach influences drug solubility and absorption. For example, weakly acidic drugs are better absorbed in the stomach, while weakly basic drugs are absorbed in the intestines.
Intestinal Motility: Alterations in gut motility can either enhance or impede the drug's residence time in absorption sites, affecting its uptake.

Bioavailability studies are essential in pharmaceutical research and development. These studies evaluate the fraction of the drug reaching systemic circulation and its absorption efficiency. Insights from bioavailability studies help in:

Determining a drug’s therapeutic utility and effective dosing.
Optimizing formulations to improve absorption and systemic delivery.
Identifying suitable administration routes to maximize efficacy and minimize first-pass metabolism effects.

These studies are vital for designing and approving new and improved formulations of existing drugs, ensuring safety, efficacy, and optimal therapeutic outcomes.

Bioavailability indicates the fraction of the total administered dose that reaches the systemic circulation as an intact drug.

Different administration routes result in varying bioavailability. For example, the drug directly enters the bloodstream through intravenous injection, providing 100% bioavailability.

However, orally administered drugs pass through the GI tract, get absorbed, and undergo metabolism in the liver, resulting in a lesser dose of the drug reaching the systemic circulation.

An oral drug’s bioavailability depends on enzyme activity in the gut wall or liver, gastric pH, and intestinal motility. It is the ratio of the drug quantity reaching the systemic circulation to the drug quantity administered.

Some drugs, like lidocaine, undergo extensive first-pass metabolism, significantly reducing their bioavailability and ruling out their oral usage.

Bioavailability studies for a new or existing drug indicate their therapeutic utility, absorption efficiency, suitable formulation, and effective administration route.

标签: bioavailability, pharmacokinetics, drug effectiveness, route of administration, intravenous administration, oral administration, absorption barriers, first-pass metabolism, enzyme activity, gastric pH,

9.1: Bioavailability: Overview

登入你的帐号

注册一个新帐号